Published in Clin Exp Metastasis on January 01, 2002
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell (2004) 1.62
Dealing with the family: CD147 interactions with cyclophilins. Immunology (2006) 1.46
Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas: role in epithelio-stromal interactions and matrix metalloproteinase induction. Am J Pathol (2005) 1.24
Pancreatic stellate cells--role in pancreas cancer. Langenbecks Arch Surg (2008) 1.21
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer (2006) 1.16
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res (2009) 1.16
The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. Int J Mol Sci (2014) 1.15
Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem (2008) 1.13
The Stimulation of CD147 Induces MMP-9 Expression through ERK and NF-kappaB in Macrophages: Implication for Atherosclerosis. Immune Netw (2009) 1.01
Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther (2011) 0.97
Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.97
Regulation of invadopodia formation and activity by CD147. J Cell Sci (2012) 0.95
Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN. Front Physiol (2013) 0.93
EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate (2011) 0.92
Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch Otolaryngol Head Neck Surg (2008) 0.92
Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs (2010) 0.91
Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells. Mol Cancer Res (2011) 0.91
Human tumor cells induce angiogenesis through positive feedback between CD147 and insulin-like growth factor-I. PLoS One (2012) 0.90
A role for endothelial-derived matrix metalloproteinase-2 in breast cancer cell transmigration across the endothelial-basement membrane barrier. Clin Exp Metastasis (2007) 0.89
Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci (2014) 0.89
Roles of CD147 on T lymphocytes activation and MMP-9 secretion in systemic lupus erythematosus. J Cell Mol Med (2007) 0.89
Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs (2011) 0.89
EMMPRIN regulates tumor growth and metastasis by recruiting bone marrow-derived cells through paracrine signaling of SDF-1 and VEGF. Oncotarget (2015) 0.88
CD147 promotes Src-dependent activation of Rac1 signaling through STAT3/DOCK8 during the motility of hepatocellular carcinoma cells. Oncotarget (2015) 0.88
Novel electrospun polyurethane/gelatin composite meshes for vascular grafts. J Mater Sci Mater Med (2010) 0.87
CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. Am J Pathol (2012) 0.87
Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle. Reprod Biol Endocrinol (2010) 0.86
Nitric oxide induces the progression of abdominal aortic aneurysms through the matrix metalloproteinase inducer EMMPRIN. Am J Pathol (2009) 0.86
Upregulation of EMMPRIN after permanent focal cerebral ischemia. Neurochem Int (2007) 0.84
Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples. World J Gastroenterol (2007) 0.84
EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts. Cancer Lett (2008) 0.82
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol (2013) 0.82
A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells. Cancer Biol Ther (2009) 0.82
Pepsin-pancreatin protein hydrolysates from extruded amaranth inhibit markers of atherosclerosis in LPS-induced THP-1 macrophages-like human cells by reducing expression of proteins in LOX-1 signaling pathway. Proteome Sci (2014) 0.82
Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci (2011) 0.82
Activation of CD147 with cyclophilin a induces the expression of IFITM1 through ERK and PI3K in THP-1 cells. Mediators Inflamm (2010) 0.81
In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec (2008) 0.79
TRAF6 regulates melanoma invasion and metastasis through ubiquitination of Basigin. Oncotarget (2016) 0.78
Apolipoprotein D Internalization Is a Basigin-dependent Mechanism. J Biol Chem (2015) 0.77
Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation. J Magn Reson Imaging (2015) 0.76
Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis (2017) 0.75
Upregulation of EMMPRIN (OX47) in Rat Dorsal Root Ganglion Contributes to the Development of Mechanical Allodynia after Nerve Injury. Neural Plast (2015) 0.75
Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype via exosomal miR-21. Oncotarget (2016) 0.75
The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. Mol Oncol (2017) 0.75
Melittin inhibits the invasion of MCF-7 cells by downregulating CD147 and MMP-9 expression. Oncol Lett (2016) 0.75
Expression of metalloproteinases (MMP-2 and MMP-9) in basal-cell carcinoma. Mol Biol Rep (2016) 0.75
Metalloproteinases 2 and 9 activity during promotion and progression stages of rat liver carcinogenesis. J Mol Histol (2008) 0.75
Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem (1995) 5.57
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest (1999) 3.35
The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res (1995) 3.04
Matrix metalloproteinases in tumour invasion and metastasis. J Pathol (1999) 2.65
Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res (2001) 2.33
Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol (1993) 2.01
Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J (1993) 1.83
Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol (2001) 1.71
Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem (1997) 1.69
Interstitial collagenase is required for angiogenesis in vitro. Dev Biol (1994) 1.55
Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer (1998) 1.48
Expression of emmprin by oral squamous cell carcinoma. Int J Cancer (2000) 1.42
Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res (1993) 1.41
Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. Cancer Res (1989) 1.31
Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett (2000) 1.27
Membrane associated matrix metalloproteinases in metastasis. Bioessays (1999) 1.24
Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem (1995) 1.19
Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res (1989) 1.19
Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol (1997) 1.16
Expression of the extracellular matrix metalloproteinase inducer (EMMPRIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem (1999) 1.15
Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst (1995) 1.13
EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res (2000) 1.10
Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers. Int J Cancer (1993) 1.10
Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem (1997) 1.09
Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys (1991) 0.92
Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines. Clin Exp Metastasis (1998) 0.89
Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect Tissue Res (1992) 0.82
Epithelial-to-mesenchymal transition in HPV-33-transfected cervical keratinocytes is associated with increased invasiveness and expression of gelatinase A. Int J Cancer (1994) 0.82
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab (2008) 2.84
Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev (2011) 2.48
Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res (2003) 2.20
Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol (2011) 2.09
Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost (2005) 2.07
Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia (2007) 1.97
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem (2005) 1.81
Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem (2002) 1.81
Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia (2010) 1.73
Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem (2003) 1.66
Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res (2004) 1.61
Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem (2003) 1.61
Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem (2005) 1.60
Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol (2008) 1.50
Wolbachia utilizes host microtubules and Dynein for anterior localization in the Drosophila oocyte. PLoS Pathog (2005) 1.49
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities. PLoS Comput Biol (2009) 1.48
Embryonic stem cells generate airway epithelial tissue. Am J Respir Cell Mol Biol (2004) 1.45
Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration. J Biol Chem (2004) 1.44
A potential probe set of fluorescence in situ hybridization for detection of lung cancer in bronchial brushing specimens. J Cancer Res Clin Oncol (2012) 1.43
Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem (2008) 1.41
Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem (2006) 1.41
Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem (2011) 1.40
Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation (2006) 1.40
Membrane type-matrix metalloproteinases (MT-MMP). Curr Top Dev Biol (2003) 1.39
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38
Role of the hemopexin domain of matrix metalloproteinases in cell migration. J Cell Physiol (2008) 1.37
Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther (2002) 1.32
Mechanism of 4-chlorobenzoate:coenzyme a ligase catalysis. Biochemistry (2008) 1.31
Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res (2009) 1.31
Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J Biol Chem (2010) 1.31
Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res (2010) 1.30
Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett (2009) 1.30
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest (2006) 1.29
Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs (2007) 1.29
Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. Gastroenterology (2011) 1.28
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A (2011) 1.28
Divergence of function in the hot dog fold enzyme superfamily: the bacterial thioesterase YciA. Biochemistry (2008) 1.28
Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res (2009) 1.26
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) (2011) 1.26
Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol (2004) 1.25
Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant (2005) 1.25
The concentration of Nuf, a Rab11 effector, at the microtubule-organizing center is cell cycle regulated, dynein-dependent, and coincides with furrow formation. Mol Biol Cell (2007) 1.23
Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev Dyn (2006) 1.22
Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer (2003) 1.21
Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest (2002) 1.21
Vesicles and actin are targeted to the cleavage furrow via furrow microtubules and the central spindle. J Cell Biol (2008) 1.19
Conditional inactivation of Has2 reveals a crucial role for hyaluronan in skeletal growth, patterning, chondrocyte maturation and joint formation in the developing limb. Development (2009) 1.18
The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res (2006) 1.15
Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res (2009) 1.15
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev (2006) 1.15
Cartilage link protein 1 (Crtl1), an extracellular matrix component playing an important role in heart development. Dev Biol (2007) 1.15
Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells. J Biol Chem (2008) 1.13
Heme oxygenase: the key to renal function regulation. Am J Physiol Renal Physiol (2009) 1.12
Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem (2013) 1.12
Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res (2013) 1.12
Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol (2005) 1.11
HPV prevalence, viral load and physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int J Cancer (2007) 1.11
Human carcinoma cell growth and invasiveness is impaired by the propeptide of the ubiquitous proprotein convertase furin. Cancer Res (2005) 1.10
Selective matrix metalloproteinase (MMP) inhibitors in cancer therapy: ready for prime time? Cancer Biol Ther (2009) 1.10
Emmprin, a cell surface inducer of matrix metalloproteinases (MMPs), is expressed in T-cell lymphomas. J Pathol (2004) 1.10
E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. Am J Pathol (2003) 1.09
Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer (2006) 1.09
Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Cancer Res (2005) 1.09
Hyaluronan in limb morphogenesis. Dev Biol (2007) 1.09
Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer (2013) 1.09
Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol (2011) 1.09
Angiogenesis is induced by airway smooth muscle strain. Am J Physiol Lung Cell Mol Physiol (2007) 1.08
Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis (2008) 1.08
Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France--The EDiTH VI study. J Clin Virol (2011) 1.07
Epithelial cell-extracellular matrix interactions and stem cells in airway epithelial regeneration. Proc Am Thorac Soc (2008) 1.07
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res (2011) 1.06
Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res (2009) 1.06
Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum (2010) 1.05
Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin Cancer Res (2008) 1.04
Mechanical stretch induces MMP-2 release and activation in lung endothelium: role of EMMPRIN. Am J Physiol Lung Cell Mol Physiol (2002) 1.04
CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res (2004) 1.03
CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett (2004) 1.03
Direct activation of emmprin and associated pathogenesis by an oncogenic herpesvirus. Cancer Res (2010) 1.03
Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs. FASEB J (2005) 1.02